OptimizeRx Corporation (OPRX) and GoodRx Holdings, Inc. (GDRX) operate in the digital health space, focusing on technology solutions for healthcare and pharmaceuticals. OPRX is experiencing growth with its AI-enabled Dynamic Audience Activation Platform, targeting a revenue forecast of $109-$114 million for 2026. Meanwhile, GDRX, aiming for $750-$780 million in revenues for 2026, faces challenges including declines in certain business segments and variability in prescription transaction revenues.
Recent reports show OPRX’s stock has declined 25.9% in the past year, while GDRX has faced a 50.8% decline. Valuation comparisons indicate OPRX is trading at a Price/Book ratio of 0.94, compared to GDRX’s 1.28. Analysts have adjusted their estimates upwards for OPRX and downwards for GDRX over the past 60 days, highlighting a more favorable outlook for OPRX, which currently holds a Zacks Rank of 1 (Strong Buy) against GDRX’s 4 (Sell).
